Skip to main content
. 2010 Dec 6;55(2):680–687. doi: 10.1128/AAC.00992-10

FIG. 2.

FIG. 2.

Mean plasma concentration-time profiles of rifabutin and 25-O-desacetyl-rifabutin for group 2 (n = 11) (A and B, respectively) and group 3 (n = 9) (C and D, respectively). The groups were treated as follows: rifabutin (150 mg) QD for both group 2 and group 3 (samples taken on day 20) (▪); rifabutin (150 mg) every 3 days plus saquinavir-ritonavir (1,000/100 mg) BID for group 2 (samples taken on day 43) (□); rifabutin (150 mg) every 4 days plus saquinavir-ritonavir (1,000/100 mg) twice daily for group 3 (samples taken on day 42) (□). The error bars represent the standard errors of the means.